Works by ZHANG Xiaoping


Results: 799
    1
    2
    3
    4
    5

    Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).

    Published in:
    Cardiovascular Drugs & Therapy, 2020, v. 34, n. 3, p. 357, doi. 10.1007/s10557-019-06919-4
    By:
    • Judge, Daniel P.;
    • Kristen, Arnt V.;
    • Grogan, Martha;
    • Maurer, Mathew S.;
    • Falk, Rodney H.;
    • Hanna, Mazen;
    • Gillmore, Julian;
    • Garg, Pushkal;
    • Vaishnaw, Akshay K.;
    • Harrop, Jamie;
    • Powell, Christine;
    • Karsten, Verena;
    • Zhang, Xiaoping;
    • Sweetser, Marianne T.;
    • Vest, John;
    • Hawkins, Philip N.
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.

    Published in:
    Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-02064-z
    By:
    • Wang, Hongkai;
    • Jiang, Shusuan;
    • Luo, Hong;
    • Zhou, Fangjian;
    • He, Dalin;
    • Ma, Lulin;
    • Guo, Hongqian;
    • Liang, Chaozhao;
    • Chong, Tie;
    • Jiang, Jun;
    • Chen, Zhiwen;
    • Wang, Yong;
    • Zou, Qing;
    • Tian, Ye;
    • Xiao, Jun;
    • Huang, Jian;
    • Chen, Jinchao;
    • Dong, Qiang;
    • Zhang, Xiaoping;
    • Li, Hanzhong
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50